Should All Patients with Resistant Hypertension Receive Spironolactone?

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064165%3A_____%2F16%3A10329598" target="_blank" >RIV/00064165:_____/16:10329598 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11110/16:10329598 RIV/00216208:11120/16:43912297

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s11906-016-0690-1" target="_blank" >http://dx.doi.org/10.1007/s11906-016-0690-1</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s11906-016-0690-1" target="_blank" >10.1007/s11906-016-0690-1</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Should All Patients with Resistant Hypertension Receive Spironolactone?

Popis výsledku v původním jazyce

Purpose of review: Resistant hypertension is a common clinical situation. Identification of true resistant hypertension (using 24-h ambulatory blood pressure monitoring to exclude white coat phenomenon, excluding secondary causes and non-adherence to treatment) is important mostly because of the application of a proper therapeutic approach and the higher cardiovascular risk of these patients. This review surveys recent studies, with a focus on mineralocorticoid receptor antagonists, including spironolactone, in the treatment of resistant hypertension. Recent findings: A range of randomized and non-randomized studies have proved the efficacy of mineralocorticoid receptor antagonists, including spironolactone. However, long-term mortality studies are still missing for the hypertensive population. In the case of spironolactone side effects, higher doses of amiloride or eplerenone might be used. Summary: Based on available data and our own experience, spironolactone (mineralocorticoid receptor antagonists) should be involved, if tolerated, in combination therapy in true resistant hypertensive patients. Spironolactone still represents primary therapeutic modality under specific conditions of primary aldosteronism.

Název v anglickém jazyce

Should All Patients with Resistant Hypertension Receive Spironolactone?

Popis výsledku anglicky

Purpose of review: Resistant hypertension is a common clinical situation. Identification of true resistant hypertension (using 24-h ambulatory blood pressure monitoring to exclude white coat phenomenon, excluding secondary causes and non-adherence to treatment) is important mostly because of the application of a proper therapeutic approach and the higher cardiovascular risk of these patients. This review surveys recent studies, with a focus on mineralocorticoid receptor antagonists, including spironolactone, in the treatment of resistant hypertension. Recent findings: A range of randomized and non-randomized studies have proved the efficacy of mineralocorticoid receptor antagonists, including spironolactone. However, long-term mortality studies are still missing for the hypertensive population. In the case of spironolactone side effects, higher doses of amiloride or eplerenone might be used. Summary: Based on available data and our own experience, spironolactone (mineralocorticoid receptor antagonists) should be involved, if tolerated, in combination therapy in true resistant hypertensive patients. Spironolactone still represents primary therapeutic modality under specific conditions of primary aldosteronism.

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FA - Kardiovaskulární nemoci včetně kardiochirurgie

OECD FORD obor

—

Projekt

<a href="/cs/project/NV16-30345A" target="_blank" >NV16-30345A: Feochromocytom jako model chronické aktivace stresové osy v patogenezi metabolických poruch</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2016

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Current Hypertension Reports

ISSN

1522-6417

e-ISSN

—

Svazek periodika

18

Číslo periodika v rámci svazku

11

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

—

Kód UT WoS článku

000388128800005

EID výsledku v databázi Scopus

2-s2.0-84993965277